Sernova appoints new chief executive

Canada-based biotech Sernova (TSX: SVA) today announced the appointment of Jonathan Rigby as its new chief executive (CEO), replacing Cynthia Pussinen.

James Parsons, chairman of the audit committee of Senova, which is developing regenerative medicine cell therapies for treatment of chronic diseases, stated: “The board believes that Sernova is now positioned to achieve its strategic milestones under Jonathan’s leadership. Jonathan brings a track record of success raising equity capital for biotech companies. Jonathan has led multiple biotech companies through listings onto Nasdaq, and the achievement of key operational and clinical developments, leading to strategic acquisitions that have generated significant value for shareholders.”

Commenting on his appointment, Mr Rigby said: “As a type 1 diabetic myself, I am honored to serve the company and its shareholders as Sernova’s new CEO. I am passionate about Sernova’s mission and determined to lead the company to realize its full potential. I have financed and grown multiple companies through to exits and my goal is clear; I will work tirelessly with the team to do the same for Sernova and its shareholders.”